Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. lifted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 26.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,871 shares of the biopharmaceutical company’s stock after purchasing an additional 2,467 shares during the period. E Fund Management Co. Ltd.’s holdings in Ultragenyx Pharmaceutical were worth $568,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its holdings in Ultragenyx Pharmaceutical by 18.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 471,825 shares of the biopharmaceutical company’s stock valued at $22,563,000 after acquiring an additional 75,100 shares in the last quarter. Maryland State Retirement & Pension System purchased a new position in Ultragenyx Pharmaceutical during the 4th quarter valued at about $292,000. M&T Bank Corp purchased a new position in Ultragenyx Pharmaceutical during the 4th quarter valued at about $310,000. Amalgamated Bank increased its holdings in Ultragenyx Pharmaceutical by 10.0% during the 4th quarter. Amalgamated Bank now owns 15,716 shares of the biopharmaceutical company’s stock valued at $752,000 after acquiring an additional 1,427 shares in the last quarter. Finally, Natixis Advisors L.P. increased its holdings in Ultragenyx Pharmaceutical by 10.8% during the 4th quarter. Natixis Advisors L.P. now owns 15,289 shares of the biopharmaceutical company’s stock valued at $731,000 after acquiring an additional 1,496 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 4,173 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $53.76, for a total transaction of $224,340.48. Following the transaction, the insider now directly owns 89,268 shares of the company’s stock, valued at $4,799,047.68. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, EVP Karah Herdman Parschauer sold 3,756 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $53.76, for a total transaction of $201,922.56. Following the transaction, the executive vice president now directly owns 67,340 shares of the company’s stock, valued at $3,620,198.40. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John Richard Pinion sold 4,173 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $53.76, for a total transaction of $224,340.48. Following the transaction, the insider now directly owns 89,268 shares in the company, valued at $4,799,047.68. The disclosure for this sale can be found here. Insiders have sold a total of 32,116 shares of company stock valued at $1,645,983 over the last ninety days. Corporate insiders own 6.80% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock traded down $0.40 during trading on Wednesday, reaching $41.56. The company had a trading volume of 731,293 shares, compared to its average volume of 772,501. Ultragenyx Pharmaceutical Inc. has a 12-month low of $31.52 and a 12-month high of $54.98. The stock’s 50 day moving average price is $46.65 and its two-hundred day moving average price is $44.33. The firm has a market capitalization of $3.45 billion, a price-to-earnings ratio of -5.18 and a beta of 0.68.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). The business had revenue of $108.83 million for the quarter, compared to analyst estimates of $116.03 million. Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 421.88%. The company’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period last year, the firm earned ($2.33) earnings per share. As a group, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RARE has been the subject of a number of recent research reports. Robert W. Baird lifted their price target on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a report on Tuesday, January 30th. JPMorgan Chase & Co. lifted their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, March 18th. Wedbush lowered their price target on shares of Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a “neutral” rating for the company in a report on Friday, May 3rd. Canaccord Genuity Group lowered their price target on shares of Ultragenyx Pharmaceutical from $111.00 to $109.00 and set a “buy” rating for the company in a report on Monday. Finally, Royal Bank of Canada initiated coverage on shares of Ultragenyx Pharmaceutical in a report on Monday, April 22nd. They set an “outperform” rating and a $77.00 price target for the company. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $87.85.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.